A message from TrialNet Chair Carla Greenbaum, M.D.

At TrialNet, the health and safety of our participants and research teams is always our top priority.

In a two-year study wrapping up at year's end, frozen blood samples from previous TrialNet study participants who did not receive the study drug played a starring role.

For most people, the onset of type 1 diabetes seems to occur suddenly, often resulting in a trip to the emergency room with life-threatening complications such as diabetic ketoacidosis (DKA). TrialNet is working to change that scenario.